Consistently with these results, previous studies showed that the loss of PR expression in originally hormone receptor (ER and PR) positive breast cancer cells was compensated by an increase in EGFR signaling, resulting in the acquisition of resistance to selective ER modulators (SERM; e.g. tamoxifen) [60], [61]. Here, ESR1 is linked to breast carcinoma.